United Homes Group stock plunges after Nikki Haley, directors resign
LONDON - Shield Therapeutics plc (LSE:STX), a commercial stage pharmaceutical company focused on iron deficiency treatments, has granted share options to its Chief Executive Officer Anders Lundstrom as part of his 2025 annual equity package, according to a press release statement.
The company awarded Lundstrom options over 1,547,262 ordinary shares under Shield’s Retention and Performance Share Plan on October 13. The options have an exercise price of 1.5 pence per share and will vest in three equal tranches over three years, contingent on Lundstrom remaining in his position at each vesting date.
The granted options represent approximately 0.1% of Shield’s total AIM-listed securities currently in issue. Lundstrom presently holds 585,000 ordinary shares in the company.
Shield Therapeutics specializes in developing and commercializing treatments for iron deficiency. The company’s shares are traded on the London Stock Exchange under the ticker STX.
The option grant was disclosed in accordance with EU Market Abuse Regulations requirements for transactions involving persons discharging managerial responsibilities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.